Opioid Withdrawal Symptom Mitigation Data Can Support A Labeling Claim

While symptom reduction is a clinically meaningful benefit that can support an indication, data on withdrawal treatment completion can provide confirmatory evidence of a drug's effect, US FDA advisory committee members say in their review of US WorldMeds' lofexidine.

PS1803_Opioid_706093318_1200.jpg

A US FDA advisory committee's endorsement of US WorldMeds LLC's Lucemyra (lofexidine) for mitigating the symptoms of abrupt opioid withdrawal came with advice for future sponsors on the evidentiary threshold for demonstrating a clinically meaningful benefit for withdrawal treatments.

While many members of the Psychopharmacologic Drugs Advisory Committee believe data on opioid withdrawal symptom mitigation are enough to support...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from US FDA Performance Tracker

More from Regulatory Trackers